CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
871-885 of 1026
What Is Pulmonary Hypertension? How Is It Classified?
MinuteCE®What Is Pulmonary Hypertension? How Is It Classified?
Case-Based Management of Hyperkalemia to Optimize RAASi Therapy in Patients with CKD
CME/CECase-Based Management of Hyperkalemia to Optimize RAASi Therapy in Patients with CKD
- advertisement
Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
CME/CERevolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment
CME/CEExpert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment
The Treatment Pipeline for Primary Biliary Cholangitis: Sorting Out the PPARs
MinuteCE®The Treatment Pipeline for Primary Biliary Cholangitis: Sorting Out the PPARs
Goals of Treatment for Primary Biliary Cholangitis: A Balancing Act
MinuteCE®Goals of Treatment for Primary Biliary Cholangitis: A Balancing Act
Primary Biliary Cholangitis vs Primary Sclerosing Cholangitis: Do You Know the Difference?
MinuteCE®Primary Biliary Cholangitis vs Primary Sclerosing Cholangitis: Do You Know the Difference?
- advertisement
Treatment for Primary Biliary Cholangitis: Who's on First, Who's on Second?
MinuteCE®Treatment for Primary Biliary Cholangitis: Who's on First, Who's on Second?
Your Patient's PBC Treatment: Long-Term Monitoring and Management
MinuteCE®Your Patient's PBC Treatment: Long-Term Monitoring and Management
The Treatment Pipeline for Primary Biliary Cholangitis: IBAT Inhibition and Beyond
MinuteCE®The Treatment Pipeline for Primary Biliary Cholangitis: IBAT Inhibition and Beyond





















































